Heike Keilhack
119 works · 6,916 citations · h-index 33
Top works
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- Diverse Biochemical Properties of Shp2 Mutants
- Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2 -Mutant Non-Hodgkin Lymphoma
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling
- Loss of BAP1 function leads to EZH2-dependent transformation
- Identification of Src Phosphorylation Sites in the Catenin p120
- Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
- Both SH2 Domains Are Involved in Interaction of SHP-1 with the Epidermal Growth Factor Receptor but Cannot Confer Receptor-directed Activity to SHP-1/SHP-2 Chimera
- Binding of Phosphatidic Acid to the Protein-Tyrosine Phosphatase SHP-1 as a Basis for Activity Modulation
- PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
- A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients
- The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat
- Negative Regulation of Ros Receptor Tyrosine Kinase Signaling
- EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
- Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program
- PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease